Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.62 |
| ▸ | CTSK | P43235 | 5/20 | 0.62 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | GRN | P28799 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19825087 | 1.00 | CTSS (0.62) | CTSSCTSKAAK1IDO1KMT2A | |
| SCHEMBL1430069 | 1.00 | CTSS (0.62) | CTSSCTSKAAK1IDO1KMT2A | |
| SCHEMBL956167 | 0.94 | CTSS (0.68) | CTSSCTSKAAK1IDO1KMT2A | |
| SCHEMBL1351322 | 0.94 | CTSS (0.68) | CTSSCTSKAAK1IDO1KMT2A | |
| SCHEMBL956164 | 0.94 | CTSS (0.68) | CTSSCTSKAAK1IDO1KMT2A | |
| SCHEMBL1864395 | 0.89 | CTSS (0.62) | CTSSCTSKAAK1IDO1KMT2A | |
| SCHEMBL1864392 | 0.89 | CTSS (0.62) | CTSSCTSKAAK1IDO1KMT2A | |
| SCHEMBL24298421 | 0.88 | CTSK (0.64) | CTSSCTSKAAK1IDO1KMT2A | |
| SCHEMBL3814592 | 0.88 | CTSK (0.68) | CTSSCTSKAAK1IDO1KMT2A | |
| SCHEMBL952036 | 0.88 | CTSK (0.64) | CTSSCTSKAAK1IDO1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111315746-B | Tryptophan hydroxylase inhibitors and pharmaceutical compositions comprising the same | 光州科学技术院 | 2022-11-29 | — | — | CN | disclosed |
| CN-114929689-A | Bcl-2 inhibitors | 百济神州有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-11407763-B2 | Tryptophan hydroxylase inhibitor and pharmaceutical composition including same | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLGY (KR) | 2022-08-09 | — | — | US | disclosed |
| EP-3674303-B1 | NOVEL TRYPTOPHAN HYDROXYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | GWANGJU INST SCIENCE & TECH (KR) | 2022-07-20 | — | — | EP | disclosed |
| US-20210155634-A1 | NOVEL TRYPTOPHAN HYDROXYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2021-05-27 | — | — | US | disclosed |
| EP-3674303-A1 | NOVEL TRYPTOPHAN HYDROXYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Gwangju Institute of Science and Technology (KR) | 2020-07-01 | — | — | EP | disclosed |
| CN-111315746-A | Novel tryptophan hydroxylase inhibitors and pharmaceutical compositions comprising the same | 光州科学技术院 | 2020-06-19 | — | — | CN | disclosed |
| US-20190270778-A1 | Cyclic Peptides As C5a Receptor Antagonists | PFIZER INC. (US) | 2019-09-05 | — | — | US | disclosed |
| EP-3491005-A1 | CYCLIC PEPTIDES AS C5 A RECEPTOR ANTAGONISTS | Pfizer Inc (US) | 2019-06-05 | — | — | EP | disclosed |
| CN-109563136-A | Cyclic peptide as C5a receptor antagonist | 辉瑞公司 | 2019-04-02 | — | — | CN | disclosed |
| US-20160251324-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI-AVENTIS (FR) | 2016-09-01 | — | — | US | disclosed |
| US-9309207-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2016-04-12 | — | — | US | disclosed |
| US-20160024033-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI-AVENTIS (FR) | 2016-01-28 | — | — | US | disclosed |
| US-9126955-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2015-09-08 | — | — | US | disclosed |
| US-20140206760-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI (FR) | 2014-07-24 | — | — | US | disclosed |
| US-8722655-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of tafia | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-20140039011-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI (FR) | 2014-02-06 | — | — | US | disclosed |
| US-8580777-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2013-11-12 | — | — | US | disclosed |
| US-20110178130-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| CN-101356156-A | Aspartic protease inhibitors | VITAE PHARMACEUTICALS INC (US) | 2009-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024033-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | TFPI, TFPI2, SERPINC1 | CTSS 68/4885CTSK 123/4885AAK1 3289/4885 |
| US-20110178130-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | TFPI, TFPI2, SERPINC1 | CTSS 68/4885CTSK 123/4885AAK1 3289/4885 |
| US-20140039011-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | TFPI, TFPI2, SERPINC1 | CTSS 68/4885CTSK 123/4885AAK1 3289/4885 |
| US-11407763-B2 | Tryptophan hydroxylase inhibitor and pharmaceutical composition including same | TPH1, TPH2, IDO1 | CTSS 1720/4885CTSK 2657/4885AAK1 878/4885 |
| US-20210155634-A1 | NOVEL TRYPTOPHAN HYDROXYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | TPH1, TPH2, IDO1 | CTSS 1838/4885CTSK 2844/4885AAK1 883/4885 |
| US-20140206760-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | TFPI, TFPI2, SERPINC1 | CTSS 71/4885CTSK 126/4885AAK1 3406/4885 |
| US-20160251324-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | TFPI, TFPI2, SERPINC1 | CTSS 68/4885CTSK 123/4885AAK1 3289/4885 |
| US-20190270778-A1 | Cyclic Peptides As C5a Receptor Antagonists | C3AR1, C5AR1, C5AR2 | CTSS 1540/4885CTSK 1530/4885AAK1 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.